Latest News

Update: Siponimod (Mayzent) for Secondary Progressive MS

November 16, 2022 | Advocacy, Funding, Treatments

At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]


Important notice for MS patients regarding Evusheld

November 16, 2022 | Advocacy, Covid-19, Treatments

Important notice for MS patients regarding EvusheldTM. EvusheldTM is a pre-exposure prophylaxis, which has shown positive results for reducing the impacts of COVID-19 on those who may lowered immunity against COVID 19 due to their MS treatments. Evusheld is NOT […]


Making progress to make Autologous Hematopoietic Stem Cell Treatment (aHSCT) an available treatment option in NZ for MS

September 14, 2022 | Advocacy, Treatments

Autologous Hematopoietic Stem Cell Treatment (aHSCT) is an intense chemotherapy treatment which aims to wipe out harmful immune cells and rebuild the immune system. aHSCT is a life-improving treatment halting the disease and disability in its tracks. A person receiving […]


Addressing the unmet need

September 14, 2022 | Advocacy, Progressive, Treatments

Currently, only approximately 1900 of the over 4130 New Zealanders diagnosed with MS are able to access funded Disease Modifying Therapies (DMTs). In particular, those with progressive forms of MS, Secondary (SPMS) and Primary Progressive MS (PPMS), have extremely limited […]


aHSCT in the news: We’re fed up waiting for it to be made available here

July 26, 2022 | Advocacy, Life with MS, Media, Treatments

A 10,000-strong petition asking Health New Zealand to extend “game-changing” stem cell treatment to multiple sclerosis (MS) patients is set to be delivered to Parliament. The petition started by Aucklander Joan Perry​, whose daughter Anne Besley​ has MS, calls for autologous haematopoietic […]